Gilead Sciences

Investor's Business Daily

Gilead Sciences (GILD) had its target price upped by UBS to 80 from 65. UBS also maintained its buy rating. The biotech's HIV treatment Truvada is now seen as a possible preventive drug for the disease. Shares rose 1.2%.

Rates

View Comments (0)